Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2017
At a glance
- Drugs Galcanezumab (Primary) ; Galcanezumab
- Indications Cluster headache; Migraine; Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 11 Jun 2017 Results of part A and part B, presented at the 59th Annual Scientific Meeting of the American Headache Society.
- 08 Mar 2017 Planned End Date changed from 1 Aug 2016 to 31 Mar 2018.
- 08 Mar 2017 Status changed from completed to active, no longer recruiting.